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A B S T R A C T
Purpose
Our aim was to determine the role of end-of-induction (EOI) minimal residual disease (MRD) as-
sessment in the identification and stratification of induction failure in patients with pediatric acute
lymphoblastic leukemia (ALL) and to identify genetic abnormalities that drive disease in these
patients.
Patients and Methods
Analysis included 3,113 patients who were treated in the Medical Research Council UKALL2003
multicenter randomized trial (NCT00222612) between 2003 and 2011.MRDwasmeasured by using
standardized real-time quantitative PCR. Median follow-up was 5 years 9 months.
Results
Fifty-nine patients (1.9%) had morphologic induction failure with 5-year event-free survival (EFS) of
50.7% (95% CI, 37.4 to 64.0) and 5-year overall survival of 57.7% (95% CI, 44.2 to 71.2). Of these,
a small proportion of patients with M2 marrow (6 of 44) and a low EOI MRD level (, 0.01%) had
5-year EFS of 100%. Conversely, among patients with morphologic remission 2.3% (61 of 2,633)
had high MRD ($ 5%) and 5-year EFS of 47.0% (95% CI, 32.9 to 61.1), which was similar to those
with morphologic induction failure. Redefining induction failure to include morphologic induction
failure and/or MRD $ 5% identified 3.9% (120 of 3,133 patients) of the trial cohort with 5-year EFS of
48.0% (95%CI, 39.3 to 58.6). Induction failure (morphologic orMRD$ 5%) occurredmost frequently in
T-ALL (10.1%; 39 of 386 T-ALL cases) and B-other ALL, that is, lacking established chromosomal
abnormalities (5.6%; 43 of 772 B-other cases). Genetic testing within the B-other group revealed the
presence ofPDGFRB gene fusions, particularlyEBF1-PDGFRB, in almost one third of B-other ALL cases.
Conclusion
Integration of EOI MRD level with morphology identifies induction failure more precisely than
morphology alone. Prevalence of EBF1-PDGFRB fusions in this group highlights the importance of
genetic screening to identify abnormalities that may be targets for novel agents.
J Clin Oncol 35:660-667. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Overall survival in children with acute lympho-
blastic leukemia (ALL) who are treated with
contemporary regimens is now. 90%.1 Whereas
the vast majority of patients experience rapid
response to chemotherapy, a minority do not
achieve morphologic remission by the end of
induction (EOI). A recent international analysis
of induction failure (IF) demonstrated that, al-
though most patients do eventually achieve a re-
mission, long-term outcome is poor2; however,
these data were based on historical cases that were
treated between 1985 and 2000, and the outcome
of IF in contemporary protocols has not been
examined in detail.
Of importance, the previous analysis pre-
dates the era of minimal residual disease (MRD)
monitoring, which is now considered the most
important prognostic factor in pediatric ALL.3,4
Studies in pediatric acute myeloid leukemia have
demonstrated flow cytometry–based MRD to be
more accurate than morphology in defining
complete remission5,6; however, at present, the
role of MRD in defining and stratifying IF in
pediatric ALL remains unknown.
Furthermore, although it is known that IF
is increased in those patients with high-risk
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chromosomal abnormalities,2 the role of newly described ABL-
class and Janus kinase (JAK)–signal transducers and activators of
transcription (STAT) genetic abnormalities7 has not been fully
explored. Identification of such lesions could provide an oppor-
tunity for the use of targeted therapy in this high-risk group.
To address these issues, we analyzed all cases of morphologic
IF in the recently reported large, multicenter, randomized con-
trolled trial, Medical Research Council UK ALL 2003 (MRC
UKALL 2003). In addition, we investigated whether EOI MRD
should be incorporated into the definition of IF and whether
a targeted genetic screening strategy identifies patients with lesions
that are amenable to treatment with novel agents.
PATIENTS AND METHODS
Participants and Trial Protocol
This study included all patients who were enrolled in the MRC
UKALL 2003 trial, as previously reported.4,8 An overview of the protocol,
including treatment regimens (Appendix Table A1, online only), can be
found in the Appendix (online only).
MRD Assessment
Bone marrow MRD was measured within five laboratories in the
United Kingdom using standardized real-time quantitative PCR for im-
munoglobulin and T-cell receptor antigen gene rearrangements.9 Quan-
titative range was 0.01%. An exact MRD cutoff of 0.01% was used to
stratify patients.
Definitions
IF was defined as failure to achieve morphologic complete remission
(, 5% bone marrow blasts) at EOI or persistent extramedullary disease.
Patients with M2 marrow (5% to 25% blasts) were allocated to the high-
risk arm, regimen C. Patients with M3 marrow (. 25% blasts) were
deemed to have experienced treatment failure and were taken off protocol,
although this was not defined as an event for the purpose of survival
analyses. Microscopic assessments of marrow were done locally with no
central review.
Genetic Analysis
Cytogenetic analysis, including fluorescence in situ hybridization
(FISH) for detection of chromosomal abnormalities of prognostic sig-
nificance, was carried out in the regional cytogenetics laboratories as part
of routine diagnosis but was reviewed and collated by the Leukaemia
Research Cytogenetics Group, as previously described.10 A representative
cohort of patients with B-other ALL—those cases lacking established
chromosomal abnormalities—were screened for rearrangements that
involved ABL1, ABL2, PDGFRB, CSF1R, CRLF2, and JAK2 by using
commercially available or home-grown7,11 break-apart FISH probes
(Cytocell, Cambridge, UK; Leica Microsystems, Milton Keynes, UK) or, in
the case of P2RY8-CRLF2, by using multiplex ligation-dependent probe
amplification (SALSA MLPA kit P335 IKZF1; MRC, Holland, the Neth-
erlands).12 EBF1-PDGFRB fusion was confirmed and validated by FISH
and RT-PCR as recently described.13
Statistical Analysis
Categorical variables were compared with standard x2 tests or Fisher’s
exact tests as appropriate. Time-to-event outcomes were defined from start
of treatment. Event-free survival (EFS) was the primary end point and was
defined as time to relapse, secondary tumor, or death. Overall survival (OS)
was time to death. Kaplan-Meier curves were produced and compared with
the log-rank method. Multivariable analysis used Cox proportional
hazards regressionmodels to test whether effects of prognostic factors were
independent, with tests of proportional hazards using an interaction with
time variable for significant factors. Graphs were plotted to 8 years to show
as much information as possible; data presented in the text relate to 5-year
outcome. All P values were two-sided. Linear trend P values were presented
for variables with a natural ordering, such as white blood cell count
(WCC), on the basis of suitable tests with one degree of freedom, for
example, Mantel-Haenszel x2, log-rank test for trend.
Statistical analyses were performed in SAS (SAS/STAT User’s Guide,
Version 9.3; SAS Institute, Cary, NC) or with in-house programs. Figures
were created with R (version 3.0.1; The R Foundation, Vienna, Austria).
Median follow-up was 5 years 9 months (range, 1 month to 10 years
1 month).
RESULTS
Patient Characteristics
Of 3,207 patients registered for the trial, 3,113 were included
in this analysis after exclusion of those with Philadelphia-positive
ALL, withdrawal of consent, or misdiagnosis (Fig 1). Patient
characteristics are listed in Table 1.
Fifty-nine patients (1.9%) were classified as IF; 44 had M2
marrow and 15 M3 marrow. No patients had persistent extra-
medullary disease. In keeping with previous reports, this group
experienced poor outcomes with a 5-year EFS of 50.7% (95% CI,
37.4 to 64.0) and a 5-year OS of 57.7% (95% CI, 44.2 to 71.2).
Outcome correlated with level of bone marrow blasts; those with
M3 marrows (. 25% blasts) had a worse outcome than did those
with M2 marrows (5-year EFS, 33.3% [95% CI, 9.4 to 57.2] v
Available for analysis
(N = 3,113)
BM status unknown
(n = 361)
UKALL2003
(N = 3,207)
BM status at day 29
available
(n = 2,752)
BM status at day 29:
M1
(n = 2,693)
BM status at day 29:
M2/M3
(n = 59)
Not eligible:
Registered twice
Misdiagnosis
Consent withdrawn
BCR-ABL1+ve
(n = 3)
(n = 14)
(n = 7)
(n = 70)
Fig 1. CONSORT diagram demonstrating selection of groups by end of induction
(day 29) bone marrow (BM) status.
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57.1% [95% CI, 41.8 to 72.4]; P = .1; Fig 2), although this was not
significant, likely as a result of the small number of cases.
The majority of patients with IF (51 of 59; 86%) did eventually
achieve remission. Patients with M2 marrow were escalated to
regimen C and 40 of 44 achieved complete remission (CR) after
consolidation therapy. The majority of patients with M2 marrow
who achieved CR continued on regimen C, whereas those who
failed to achieve remission were treated off protocol, as were those
Table 1. Patient Characteristics on the Basis of Bone Marrow Status at Day 29
Characteristic Total (N = 3,113)
Bone Marrow Status at Day 29
M1 v M2/M3 P*Unknown (n = 361) M1 (n = 2,693) M2/M3 (n = 59)
Patient
Sex
Male 1,767 (57%) 206 (57%) 1,530 (57%) 31 (53%) .5
Female 1,346 (43%) 155 (43%) 1,163 (43%) 28 (47%)
Age group at treatment start, years
, 10 2,278 (73%) 249 (69%) 2,008 (75%) 21 (36%) , .001
10-15 608 (20%) 70 (19%) 515 (19%) 23 (39%)
$ 16 227 (7%) 42 (12%) 170 (6%) 15 (25%)
Median (range) 5 (1-24) 5 (1-24) 5 (1-24) 13 (1-23) , .001
Ethnicity
Black 74 (2%) 8 (2%) 65 (2%) 1 (2%) .8
White 2,525 (81%) 282 (78%) 2,192 (81%) 51 (86%) (.3†)
Asian 232 (7%) 32 (9%) 197 (7%) 3 (5%)
Other 151 (5%) 21 (6%) 128 (5%) 2 (3%)
Unknown 131 (4%) 18 (5%) 111 (4%) 2 (3%)
Down syndrome
No 3,026 (97%) 347 (96%) 2,625 (97%) 54 (92%) .02
Yes 87 (3%) 14 (4%) 68 (3%) 5 (8%)
Disease
WCC at diagnosis
, 20 1,904 (61%) 229 (63%) 1,648 (61%) 27 (46%) , .001
20- 524 (17%) 57 (16%) 460 (17%) 7 (12%)
50- 313 (10%) 36 (10%) 268 (10%) 9 (15%)
100- 199 (6%) 21 (6%) 172 (6%) 6 (10%)
$ 200 173 (6%) 18 (5%) 145 (5%) 10 (17%)
Median (range) 12 (0-881) 12 (1-609) 12 (0-881) 30 (1-582) .0009
NCI risk group
Standard 1,812 (58%) 203 (56%) 1,596 (59%) 13 (22%) , .001
High 1,301 (42%) 158 (44%) 1,097 (41%) 46 (78%)
Immunophenotype
B-precursor 2,727 (88%) 311 (86%) 2,374 (88%) 42 (71%) , .001
T cell 386 (12%) 50 (14%) 319 (12%) 17 (29%)
Cytogenetic risk group‡
Good 1,586 (58%) 182 (59%) 1,395 (59%) 9 (21%) , .001§
Intermediate 860 (32%) 87 (28%) 752 (32%) 21 (50%)
High 121 (4%) 14 (5%) 101 (4%) 6 (14%)
Unknown 160 (6%) 28 (9%) 126 (5%) 6 (14%)
CNS disease at diagnosis
No 3,061 (98%) 351 (97%) 2,652 (98%) 58 (98%) 0.6
Yes 52 (2%) 10 (3%) 41 (2%) 1 (2%)
Treatment
Slow early response
No 2,751 (88%) 322 (89%) 2,403 (89%) 26 (44%) , .001
Yes 362 (12%) 39 (11%) 290 (11%) 33 (56%)
Bone marrow status day 29
M1 2,693 (87%) — 2,693 (100%) 0 (0%) N/A
M2 44 (1%) — 0 (0%) 44 (75%)
M3 15 (, 0.5%) — 0 (0%) 15 (25%)
Unknown 361 (12%) 361 (100%) 0 (0%) 0 (0%)
MRD level day 29, %
, 0.01 1,616 (52%) 176 (49%) 1,434 (53%) 6 (10%) , .001
$ 0.01 1,062 (34%) 108 (30%) 915 (34%) 39 (66%)
Unknown 435 (14%) 77 (21%) 344 (13%) 14 (24%)
Abbreviations: ALL, acute lymphoblastic leukemia; MRD, minimal residual disease; N/A, not applicable; NCI, National Cancer Institute; WCC, white blood cell count.
*P value for trend for ordered groups: age group, WBC, cytogenetic risk group; otherwise, P value for heterogeneity. ‘Unknown’ category excluded.
†White v black, Asian, and other.
‡Risk groups defined for B-precursor ALL. Good risk cytogenetics = ETV6-RUNX1, high hyperdiploidy; high risk = near haploidy, low hypodiploidy, KMT2A(MLL),
iAMP21, t(17;19); intermediate = all others.
§B-precursor ALL only: good v intermediate v high.
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with M3 marrow (Appendix Table A2, online only). Seventeen pa-
tients with IF (10 M2, 7 M3) underwent hematopoietic stem cell
transplantation in their first remission (6 matched related donor, 9
matched unrelated donor, 1 not known). The 5-year EFS in these
patients was 41.2% (95%CI, 18.6 to 62.6) comparedwith 55.9% (95%
CI, 39.3 to 29.6; P= .627) for those patients withM2 andM3marrows
who did not undergo hematopoietic stem cell transplantation in CR1.
IF was associated with several high-risk characteristics, in-
cluding age, WCC, T-cell phenotype, and high-risk cytogenetic
subgroups (Table 1). IF was particularly frequent in older patients;
6.6% of patients age $ 16 years experienced IF compared with
0.9% in those age , 10 years and 3.8% in those age 10 to 15 years
(Ptrend, .0001). In addition, patients with Down’s syndrome were
at greater risk of IF (5.7% v 1.8%; P = .005).
Several factors seem to influence outcome after IF (Table 2).
Age was significantly associated with EFS; patients age , 10 years
experienced superior outcome compared with those age 10 to 15
years and age$ 16 years (5-year EFS, 69.7% [95% CI, 49.3 to 90.1]
v 45.1% [95% CI, 23.7 to 66.5] v 33.3% [95% CI, 9.4 to 57.2;
P = .007). Other factors also showed a nonsignificant trend to worse
outcome, including WCC and intermediate- or high-risk cytoge-
netics. A multivariable Cox proportional hazards regression analysis
confirmed that age (hazard ratio [HR] per year of age, 1.10 [95%CI,
1.02 to 1.18]) and MRD (HR for MRD$ 5%, 4.46 [95% CI, 1.26 to
15.77]) were independently associated with EFS in morphologic IF.
MRD and IF
Because MRD is the strongest predictor of outcome in pe-
diatric ALL and as MRD was the only treatment response factor
that was independently related to EFS in our patients with M2 and
M3 marrows, we explored the role of MRD assessment in strat-
ifying those with morphologic IF. MRD data were available in 45
(76%) of 59 cases; of cases without MRD, most were T-ALL (10 of
14). These data identified a minority of patients (n = 6; Fig 3) with
M2 marrows but MRD , 0.01% who had a 5-year EFS of 100%
(Table 2).
We next compared EOI MRD in patients with M2 and M3
marrows with patients in complete morphologic remission (M1
marrow). MRD levels were highly variable, including in a small
0 1 2 3 4 5 6 7 8
20
40
60
80
100
Time (years)
EF
S 
(%
)
88 %
M1
57 %
M2
33 %
M3
No. at risk:
M1 2,693 2,623 2,540 2,259 1,841 1,464 1,106 815 521
M2 44 37 30 20 16 11 8 5 4
M3 15 10 9 6 3 2 1 0 0
M1
M2
M3
Patients
2,693
44
15
Events
289
18
10
O/E
0.9
5.0
9.9 P < .001
Fig 2. Comparison of event-free survival (EFS) stratified by end of induction
morphologic marrow status. Data indicate 8-year EFS estimates. Numbers in
each group are indicated in the risk table. M1, 5% blasts; M2 5% to 25% blasts;
M3 . 25% blasts. O/E, observed/expected.
Table 2. Univariable Analysis of Factors Influencing EFS in Morphologic In-
duction Failure
Characteristic
Events/
Patients 5-Year EFS (95%CI)
P (log
rank)
Overall 28/59 50.7 (37.4 to 64.0)
Patient
Sex
Male 16/31 45.5 (26.9 to 64.1) .5
Female 12/28 56.0 (37.2 to 74.8)
Age
, 10 6/21 69.7 (49.3 to 90.1) .007*
10-15 12/23 45.1 (23.7 to 66.5)
$ 16 10/15 33.3 (9.4 to 57.2)
Down syndrome
Yes 3/8 62.5 (29.0 to 96.0) .7
No 25/51 48.8 (34.5 to 63.1)
Disease
WCC at diagnosis
, 20 10/27 59.9 (40.1 to 79.7) .2*
20- 4/7 42.9 (6.2 to 79.6)
50- 4/9 55.6 (23.1 to 88.1)
100- 4/6 33.3 (0 to 70.9)
NCI risk group
Standard 4/13 65.9 (37.9 to 93.9) .2
High 24/46 46.2 (31.3 to 61.1)
Immunophenotype
T cell 9/17 45.3 (21.0 to 69.6) .6
B precursor 19/42 53.6 (38.1 to 69.1)
Cytogenetic risk group
(B-precursor ALL
only)
Good 2/9 76.2 (47.2 to 100.0) .3*
Intermediate 11/21 47.6 (26.2 to 69.0)
High 3/6 44.4 (0.9 to 87.9)
Treatment
Early response
Rapid 11/26 56.8 (37.4 to 76.2) .5
Slow 17/33 46.2 (28.6 to 63.8)
Bone marrow status
day 29
M2 18/44 57.1 (41.8 to 72.4) .1
M3 10/15 33.3 (9.4 to 57.2)
Regimen administered
A 0/4 100.0 .3*
B 5/9 44.4 (11.9 to 76.9)
C 23/46 47.3 (32.0 to 62.6)
MRD level day 29
, 0.01% 0/6 100.0 .001*
0.01 to , 1% 2/9 76.2 (47.2 to 100.0)
1 to , 5% 1/4 75.0 (32.5 to 100.0)
$ 5% 16/26 36.9 (17.7 to 56.1)
Abbreviations: ALL, acute lymphoblastic leukemia; EFS, event-free survival;
MRD, minimal residual disease; NCI, National Cancer Institute; WCC, white
blood cell count.
*Trend P values are a test across ordered groups.
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group of patients (54 of 2,349; 2.3%) with M1 marrows and high
MRD levels ($ 5%), which suggested IF despite morphologic
remission (Fig 3 and Appendix Tables A3 and A4, online only). As
shown in Fig 4, increasing EOI MRD levels in patients with
morphologic remission was strongly correlated with outcome. Of
importance, those with MRD $ 5% had EFS of 47.0% at 5 years;
95% CI, 32.9 to 61.1 (OS, 61.8% [95% CI, 47.9 to 75.7]), which
was comparable to patients with M2 and M3 marrows. Outcome
was similar in those patients with no EOI morphologic marrow
status recorded (n = 284) but EOI MRD$ 5% (n = 7; 5-year EFS,
38.1% [95% CI, 0 to 77.2]), and they were therefore also included
in further analyses. Using MRD values . 5% was not further
discriminatory (data not shown).
High MRD ($ 5%) in the context of morphologic remission
was particularly common in patients with T-ALL (8.0%; 22 of 276
patients with T-ALL with MRD available) compared with patients
with B-precursor ALL (1.5%; 36 of 2,357; P, .001). As previously
described, patients with EOI MRD $ 0.01% were randomly
assigned to either continue their initial regimen (A/B) or move to
the more intensive regimen C. Patients with MRD$ 5% who were
treated with regimen C had a better outcome than did those who
were treated with regimen A/B, which suggests that intensified
treatment may be beneficial, although this difference was not
significant (regimen A and B [n = 19] 5-year EFS 32.0% [95% CI,
6.5 to 57.5] v regimen C [n = 42] 5-year EFS 51.1% [95% CI, 35.6
to 66.7]; P = .7).
If all patients with MRD $ 5% are classified as IF along with
those with morphologic IF, 3.9% of trial entrants (120 to 3,113)
would be so defined, including 10.1% (39 of 386) of patients with
T-ALL and 5.6% of those with B-other ALL (43 of 772). This
combined IF group had 5-year EFS of 48.0% (95% CI, 39.3 to 58.6;
Appendix Fig A1, online only). The characteristics of this group are
listed in Appendix Table A5 (online only) and outcome in Ap-
pendix Table A6 (online only). A multivariate Cox proportional
hazards regression analysis demonstrated the independent sig-
nificance of MRD (HR for MRD $ 5%, 4.78 [95% CI, 1.49 to
15.39] and National Cancer Institute risk group (HR for high risk,
2.33 [95% CI, 1.13 to 4.80]) on EFS in IF.
Genetics of IF Defined by MRD and Morphology
A full breakdown of cytogenetic subgroups in the 120 patients
with IF (M2 and M3 marrow and/or MRD $ 5%) is shown in Fig
5. Compared with responders, a larger proportion of patients with
IF have B-other or T-ALL. In contrast, IF is exceedingly rare in
ETV6-RUNX1.
Outcome was significantly better for patients with good risk
cytogenetics—almost all of whom had high hyperdiploidy—than
for patients with intermediate- or high-risk cytogenetics (5-year EFS
70.8% [95% CI, 49.3 to 92.4] v 40.9 [95% CI, 24.8 to 57.0] v 53.0
[95% CI, 22.7 to 83.4] respectively, Pgood v intermediate/high = .03).
Outcomes did not differ between B-precursor ALL and T-ALL
< 5% (M1) 5%–25% (M2) > 25% (M3)
Day 29 Blast (%)
0
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Fig 3. Relationship between morphologic and molecular detection of minimal
residual disease (MRD) at the end of induction therapy. End of induction MRD
levels are plotted against end of induction (day 29) bone marrow status. Each point
represents a single patient. Date indicate number of patients within each category.
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Fig 4. Comparison of event-free survival (EFS) in patients in morphologic re-
mission (M1marrow;, 5% blasts) stratified into four groups on the basis of end of
induction minimal residual disease level (, 0.01%, 0.01% to 1%, 1% to 5%, .
5%). Data indicate 8-year EFS estimates. Numbers in each group are indicated
within the at risk table beneath the graph. O/E, observed/expected.
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(5-year EFS 47.8% [95% CI, 36.0 to 59.6] v 47.3 [95% CI, 33.1 to
63.5]; P = .7).
Given the over-representation of B-other ALL within the IF
group, we screened 44 of 52 cases with B-other ALL or unknown
failed cytogenetic cases for one or more of ABL-class and/or JAK-
STAT rearrangements that involve ABL1, ABL2, PDGFRB, CSF1R,
CRLF2, and JAK2. These 44 patients were representative of the 52
patients with B-other ALL or failed cytogenetics in terms of sex,
age, WCC, and survival.
We did not detect any patients with IF who harbored a gene
fusion that involved CSF1R (0 of 36) or JAK2 (0 of 35). Two
patients had an ABL1 (1 of 33) or ABL2 (1 of 23) fusion; however,
11 (31%) of 36 patients with B-other with IF had a rearrangement
that involved the PDGFRB gene, which was significantly more
frequent than among the remaining B-other cases (3 of 224; 1.3%;
P , .001). In 9 of 11 patients, rearrangement was confirmed to be
EBF1-PDGFRB fusion,12 whereas one case had ATF7IP-PDGFRB.
The remaining case did not involve EBF1, and insufficient material
was available for further analysis. Patients with EBF1-PDGFRB
fusions have been shown to respond to targeted therapy with
imatinib, which provides a potential treatment in these high-risk
patients.14,15
Among 38 B-other patients with IF, a total of four (11%)
harbored a CRLF2 rearrangement (PR2Y8-CRLF2, n = 3; and
IGH-CRLF2, n = 1). Frequencies of PR2Y8-CRLF2 (approximately
10%) and IGH-CRLF2 (approximately 3%) among patients with
B-other ALLwith IF are comparable to those observed in our previous
studies.12,16
Because IF has previously been associated with the early
T-precursor (ETP) ALL subtype,17,18 we used data from a pub-
lished United Kingdom analysis19 to explore the role of this
phenotype in driving IF. Although this analysis had previously
identified 35 cases of ETP-ALL, two cases have since been
reclassified, which gives 33 ETP-ALL cases in total. Of 39 patients
with T-ALL in the IF group, 16 had immunophenotyping available
that was adequate to classify as ETP. Of these, four (25%) of 16
were consistent with ETP-ALL, which suggests that ETP-ALL could
constitute approximately one quarter of IF seen in T-ALL. Fur-
thermore, although MRD assessment was only possible in 17 of 33
ETP-ALL cases, four (23.5%) of 17 cases had MRD $ 5% com-
pared with 6 (3.8%) of 158 non–ETP T-ALL cases (P = .005),
which confirmed the increased prevalence of IF in ETP-ALL
(Appendix Tables A4 and A7, online only). Of importance, this
subgroup of ETP-ALLwith MRD$ 5% had a 5-year EFS of 50.0%
(95% CI, 1.0 to 99.0) compared with 92.3% (95% CI, 77.8 to
100.0) for patients with ETP-ALL with MRD , 5% (P = .05).
DISCUSSION
If outcomes in pediatric ALL are to further improve, stratification
must accurately identify patients with high-risk disease who re-
quire intensification of therapy while sparing the majority of
patients from potentially toxic treatment. Treatment response that
uses morphology or MRD has formed an integral part of strati-
fication in recent trials and has been shown to effectively risk-
stratify patients, with those with morphologic IF among those with
poorest outcome. Disappointingly, despite improvements in
overall outcome in pediatric ALL, our study demonstrates that
there has been little advance in the treatment of children with IF.
MRD has now been established as the most powerful factor in
predicting outcome in pediatric ALL. Our study adds to this
T-ALL 11%
HeH 28%
B-other 25%
ETV6-RUNX1 25%
Unknown 4%
Complete Remission
iAMP21 2%
MLL 1%
Haplo/Hypo 1%
t(17;19) <1%
t(1;19) 3%
T-ALL 32%
HeH 13%
B-other 37%
ETV6-RUNX1   2%
Unknown 6%
Induction Failure
iAMP21 1%
MLL 7%
Haplo/Hypo 1%
Fig 5. Breakdown of cytogenetic subgroups in patients who achieved complete remission at the end of induction and those patients with induction failure. iAMP21,
intrachromosomal amplification of chromosome 21; ALL, acute lymphoblastic leukemia; HeH, high hyperdiploidy; Haploid/Hypo, near haploidy/low hypodiploidy.
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evidence by demonstrating the value of MRD assessment in the
context of morphologic IF. By using MRD assessment, we iden-
tified a small subgroup of patients within the IF group who had low
MRD levels. Crucially, these patients had an excellent outcome,
with 5-year EFS of 100%. Without central review, the accuracy of
M2 status cannot be assured in these six cases and may explain the
nonconcordance of morphologic and MRD levels. Although this
only affects a small number of cases, integration of MRD results
could potentially spare these patients the toxicity of more intensive
therapy.
Furthermore, whereas the majority of studies use low MRD
values to guide treatment stratification, our study shows that high
MRD levels can be effectively used to identify patients with an
extremely poor outcome. It is important to note that the real-
time quantitative PCR method that was used for MRD mea-
surement is designed to optimally detect disease between 0.01%
and 1% and may therefore not give an exact measurement of
disease at higher levels. However, our data clearly show that
those patients with morphologic remission, but high EOI MRD
($ 5%), have outcomes similar to patients with morphologic
IF. Overall, this suggests that MRD measurement provides
a more reliable assessment of disease response than mor-
phology, as previously described in pediatric acute myeloid
leukemia.5,6,20
Do these data indicate that treatment response in ALL
should be based solely on MRD assessment? High levels of MRD
certainly select a poor risk population in the context of mor-
phologic remission. Conversely, those with morphologic IF and
MRD , 5% have a relatively good outcome (Table 2), which
suggests that remission status could be based solely on MRD
level. However, given the relatively small number of cases and
the fact that outcomes are likely dependent on treatment and
MRD technique used, our data must be confirmed in other
cohorts before we can abandon morphologic assessment alto-
gether. This question will therefore be the subject of a forth-
coming international analysis by the Ponte di Legno working
group.
In light of our results, within the United Kingdom group, we
have amended the current protocol to redefine IF as EOI MRD $
5% and/or M3 marrow. Those patients with M2 marrow without
an EOI MRD result will have morphology assessed by central
review. Given the extremely poor outcome in this population, it is
essential that these patients be accurately identified so that they can
be considered for early treatment intensification and use of novel
agents.
Results of the cytogenetic screening are therefore significant,
identifying EBF1-PDGFRB rearrangements in approximately 10%
of patients with IF. This result is particularly interesting given
reports of the effectiveness of ABL tyrosine kinase inhibitors,
such as imatinib, in the treatment of children with refractory
ALL that harbors ABL-class fusions.14,15 Early intervention in
these patients led to CR and long-term survival, which high-
lights the importance of identifying targetable lesions early in
therapy.
Despite making up only 12.5% of patients in the trial, 32% of
IF occurred in T-ALL. Even so, our analysis suggests that ap-
proximately one quarter of these cases may be a result of ETP-ALL
and that MRD$ 5% identifies a subgroup of ETP-ALLwith a poor
outcome, full immunophenotyping and MRD results were not
available in all T-ALL patients and these data require confirmation
in other cohorts. However, importantly, previous studies have
shown that ETP-ALL is frequently associated with an absence of
molecular markers for MRD assessment,18,19 which means that
PCR-based MRD detection may fail to identify high-risk patients.
Flow-based MRD assessment should therefore be considered in all
patients with ETP-ALL.Whereas ETP-ALL accounts for a subgroup
of these patients, the other mechanisms that drive IF in T-ALL
remain largely unknown and detailed genetic characterization of
the T-ALL subgroup is urgently needed. Furthermore, as the
complexity of genetic characterization of pediatric ALL increases,
individual genetic subgroups will contain smaller patient numbers,
underlining the need for collaborative international trials that are
adequately powered to test new therapies in these high-risk
patients.
Given the enrichment of PDGFRB fusions in IF and the
potential for targeted therapy, the United Kingdom group has
adopted a targeted molecular screening strategy directed at high-
risk patients (Appendix Fig A2, online only). Therefore, any patient
on the current UKALL 2011 trial with B-other or T-ALL with EOI
MRD. 1% will undergo screening for ABL-class fusions. Patients
with targetable lesions will be considered for treatment with novel
agents.
Overall, our results suggest that MRD provides a more ob-
jective measure of IF than morphology. Of importance, combining
patients who fail to achieve a morphologic remission with those
with MRD $ 5% selected almost 4% of trial entrants, which
suggests that IF is more common than previously reported. This
strategy allows identification of a subgroup of patients with ex-
tremely poor outcome with conventional treatment. As a result of
this study, the United Kingdom trials group has revised the def-
inition of IF and implemented a new screening algorithm to
identify targetable lesions in an attempt to improve outcomes in
this high-risk group.
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Appendix
Supplementary Methods, Participants, and Trial Protocol
The trial recruited children and young people with acute lymphoblastic leukemia (ALL) at 45 centers in the United Kingdom
and Ireland between October 2003 and June 2011. Patients age , 1 year or with mature B-cell ALL or Philadelphia
chromosome–positive ALL were not eligible. Initially, upper age limit was 18 years, but was increased to the 20th birthday in April
2006 and 24th birthday from September 2007.
Patients were initially stratified according to clinical risk of relapse on the basis of the National Cancer Institute (NCI) risk
criteria (NCI standard risk: patients age, 10 years with white blood cell count, 503 109/L; NCI high risk: patients age$ 10 years
and/or white blood cell count $ 50 3 109/L) and cytogenetics (patients with MLL/KMT2A gene rearrangement, near haploidy
[, 30 chromosomes], low hypodiploidy [, 40 chromosomes], t(17;19)(q22;p13)/TCF3-HLF, or intrachromosomal amplification
of chromosome 21 [iAMP21] were classified as high risk). In the absence of high-risk cytogenetics, NCI standard-risk patients were
allocated to the standard risk arm, regimen A, which included a three-drug induction (dexamethasone, vincristine, and aspar-
aginase). NCI high-risk patients were allocated to the intermediate-risk arm, regimen B, and those with high-risk cytogenetics were
allocated to the high-risk arm, regimen C; regimens B and C used a four-drug induction (dexamethasone, vincristine, asparaginase,
and daunorubicin). Further details of chemotherapy regimens can be found in the tables below.
Further stratification was based on morphologic early response and minimal residual disease (MRD). Bone marrow mor-
phology was assessed in patients age, 16 years; those with. 25% bone marrow blasts at day 8 (NCI high risk) or 15 (NCI standard
risk) were allocated to the high-risk arm, regimen C, and were not eligible for MRD stratification. All patients age$ 16 years were
treated as intermediate risk irrespective of days 8 and 15 response and were eligible for MRD stratification.
Patients with MRD , 0.01% at end of induction (day 29) were classified as low risk and remained on their starting regimen
(A or B). Those with at least 0.01% end of induction MRD were classified as MRD high risk and randomly assigned between
standard postremission therapy and regimen C. Clinical high-risk patients were not eligible for MRD stratification.
The protocol was approved by the Scottish Multi-Centre Research Ethics Committee. Patients were enrolled at individual
treatment centers by principal investigators after written informed consent from caregivers or patients was obtained. The trial was
monitored by an independent data monitoring committee.
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Fig A1. Event-free survival (EFS) in 120 patients with induction failure on the
basis of new criteria (M2 and M3 marrow and/or end of induction minimal residual
disease$ 5%) compared with those patients who achieved complete remission at
the end of induction. Data indicate 8-year EFS estimates. Numbers within each
group are indicated in the at-risk table beneath the graph. O/E, observed/expected.
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Initial action by the local genetics lab
FISH with PDGFRB dual color break apart probe
Review BCR-ABL1 FISH results for ABL1 involvement†
Review cytogenetic result for 1q25 (ABL2) involvement
Criteria for testing
Poor responding patients who have:
  Induction failure or M2/M3 marrow at the end of induction
  MRD > 1% at day 28 or > 0.5% at week 14
AND
  B-other ALL* or T-ALL
Centralized screening by the LRCG
If 1q25 is abnormal by cytogenetics, FISH with ABL2 probe
If BCR-ABL1 FISH shows extra ABL1 signal, FISH with ABL1
  break apart probe
What research is performed by the LRCG?
Collate all genetic results to assess outcome
Determine the partner gene of all positive patients
Explore the genomic landscape of all ABL-class patients
What happens if the patient has an ABL-class fusion?
Discuss result with UKALL2011 trial coordinator and consider
treatment with a tyrosine kinase inhibitor
UKALL2011 screening algorithm for ABL-class fusions
Fig A2. Current UK2011 trial screening algorithm for ABL-class fusions in acute
lymphoblastic leukemia (ALL). *B-other ALL, B-cell precursor ALL lacking ETV6-
RUNX1, high hyperdiploidy, BCR-ABL1, KMT2A (MLL) rearrangement, TCF3-PBX1,
TCF3-HLF, near-haploidy, low hypodiploidy, iAMP21; †ETV6-RUNX1 FISH results
should also be reviewed to exclude rare cases of ETV6-ABL1. FISH, fluorescence
in situ hybdridization; LRCG, Leukaemia Research Cytogenetics Group; MRD,
minimal residual disease.
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Table A1. Treatment Schedules
Drug Dose Day of Cycle
Regimen A
3-Drug induction
Dexamethasone 6 mg/m2/d 1-28
Vincristine 1.5 mg/m2 2, 9, 16, 23, 30
Pegylated L-asparaginase 1,000 IU/m2 4, 18
Intrathecal methotrexate , 2 years: 8 mg; 2 years: 10 mg; . 2 years: 12 mg 1, 8, 28
6-Mercaptopurine 75 mg/m2/d 29-35
CNS-directed therapy
Intrathecal methotrexate As above 1, 8, 15
6-Mercaptopurine 75 mg/m2/d 1-21
Interim maintenance blocks
Dexamethasone 6 mg/m2/d 3 5 days 1-5, 29-33
Vincristine 1.5 mg/m2 1, 29
6-Mercaptopurine 75 mg/m2/d 1-49
Oral methotrexate 20 mg/m2/wk 1, 8, 22, 29, 36, 43, 50
Intrathecal methotrexate As above 15
Delayed intensification blocks
Dexamethasone 10 mg/m2/d 3 7 days 2-8, 16-22
Vincristine 1.5 mg/m2 2, 9, 16
Doxorubicin 25 mg/m2 2, 9, 16
Pegylated L-asparaginase 1,000 IU/m2 4
Intrathecal methotrexate As above 1
Cyclophosphamide 1,000 mg/m2 29
6-Mercaptopurine 60 mg/m2/d 29-42
Cytarabine 75 mg/m2/d 3 4 days 30-33, 37-40
Intrathecal methotrexate As above 29, 36
Maintenance cycles
Dexamethasone 6 mg/m2/d 3 5 days 1-5, 29-33, 57-61
Vincristine 1.5 mg/m2 1, 29, 57
6-Mercaptopurine 75 mg/m2/d Continuous
Oral methotrexate 20 mg/m2/wk 1, 8, 15, 22, 29, 36, 43, 50
Intrathecal methotrexate As above 15
Regimen B
4-Drug induction
Dexamethasone 6 mg/m2/d 1-28
Vincristine 1.5 mg/m2 2, 9, 16, 23, 30
Daunorubicin 25 mg/m2 2, 9, 16, 23
Pegylated L-asparaginase 1,000 IU/m2 4, 18
Intrathecal methotrexate , 2 years: 8 mg; 2 years: 10 mg; . 2 years: 12 mg 1, 8, 28
6-Mercaptopurine 60 mg/m2/d 29-35
BFM consolidation
Cyclophosphamide 1,000 mg/m2 1, 15
Cytarabine 75 mg/m2/d 3 4 days 2-5, 9-12, 16-19, 23-26
6-Mercaptopurine 60 mg/m2/d 36-70
Intrathecal methotrexate As above 1, 8, 15
Interim maintenance blocks
Dexamethasone 6 mg/m2/d 3 5 days 2-6, 30-34
Vincristine 1.5 mg/m2 2, 30
6-Mercaptopurine 75 mg/m2/d 1-49, 50-56
Oral methotrexate 20 mg/m2/wk 8, 15, 22, 36, 43, 50
Intrathecal methotrexate As above 1, 29
Delayed intensification blocks
Dexamethasone 10 mg/m2/d 3 7 days 2-8, 16-22
Vincristine 1.5 mg/m2 2, 9, 16
Doxorubicin 25 mg/m2 2, 9, 16
Pegylated L-asparaginase 1,000 IU/m2 4
Intrathecal methotrexate As above 1
Cyclophosphamide 1,000 mg/m2 29
6-Mercaptopurine 60 mg/m2/d 29-42
Cytarabine 75 mg/m2/d 3 4 days 30-33, 37-40
Intrathecal methotrexate As above 29, 36
Maintenance cycles
Dexamethasone 6 mg/m2/d 3 5 days 1-5, 29-33, 57-61
Vincristine 1.5 mg/m2 1, 29, 57
6-Mercaptopurine 75 mg/m2/d Continuous
Oral methotrexate 20 mg/m2/wk 1, 8, 15, 22, 29, 36, 43, 50
Intrathecal methotrexate As above 15
(continued on following page)
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Table A1. Treatment Schedules (continued)
Drug Dose Day of Cycle
Regimen C
4-Drug induction
Dexamethasone 6 mg/m2/d 1-28
Vincristine 1.5 mg/m2 2, 9, 16, 23, 30
Daunorubicin 45 mg/m2 16, 23
Pegylated L-asparaginase 1,000 IU/m2 18
Intrathecal methotrexate , 2 years: 8 mg; 2 years: 10 mg; . 2 years: 12 mg 1, 8, 28
6-Mercaptopurine 60 mg/m2/d 29-35
BFM consolidation
Cyclophosphamide 1,000 mg/m2 1, 29
Cytarabine 75 mg/m2/d 3 4 days 2-5, 9-12, 30-33, 37-40
6-Mercaptopurine 60 mg/m2/d 1-21, 29-42
Vincristine 1.5 mg/m2 16, 23, 44, 51
Pegylated L-asparaginase 1,000 IU/m2 16, 44
Intrathecal methotrexate As above 1, 8, 15
Capizzi maintenance
Vincristine 1.5 mg/m2 2, 12, 22, 32, 42
Intravenous methotrexate Initial 100 mg/m2, escalated by 50 mg/m2 in each subsequent
dose
2, 12, 22, 32, 42
Pegylated L-asparaginase 1,000 IU/m2 3, 23
Intrathecal methotrexate As above 1, 31
Delayed intensification blocks
Dexamethasone 10 mg/m2/d 3 7 days 2-8, 16-22
Vincristine 1.5 mg/m2 2, 9, 16
Doxorubicin 25 mg/m2 2, 9, 16
Pegylated L-asparaginase 1,000 IU/m2 4, 43
Intrathecal methotrexate As above 1
Cyclophosphamide 1,000 mg/m2 29
6-Mercaptopurine 60 mg/m2/d 29-42
Cytarabine 75 mg/m2/d 3 4 days 30-33, 37-40
Intrathecal methotrexate As above 29, 36
Maintenance cycles
Dexamethasone 6 mg/m2/d 3 5 days 1-5, 29-33, 57-61
Vincristine 1.5 mg/m2 1, 29, 57
6-Mercaptopurine 75 mg/m2/d Continuous
Oral methotrexate 20 mg/m2/wk Weekly
Intrathecal methotrexate As above 15
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Table A2. Subsequent Off-Protocol Treatment of 15 Patients With M3 Marrow
Patient Subsequent Treatment CR1 HSCT Comments
1 ALL-R3 protocol Yes Died of adenovirus viremia
2 ALL-R3 protocol Yes Relapsed, CR2 HSCT, alive
3 FLA-Ida No Died of relapse
4 MidAC No Died of relapse
5 UKALL2003 regimen C No Alive
6 UKALL2003 regimen C Yes Alive
7 MidAC Yes Alive
8 Nelarabine, asparaginase Yes Died of GvHD
9 Not known Yes Alive
10 Not known No Died of relapse
11 UKALL2003 regimen C Yes Alive
12 Nelarabine, cyclophosphamide, etoposide No Died of progressive disease
13 FLA-Ida Yes Died of progressive disease
14 ALL-R3 protocol No Died of progressive disease
15 UKALL2003 regimen C No Down’s syndrome, died of progressive disease
Abbreviations: CR1, first complete remission; FLA-Ida, fludarabine, cytarabine, idarubicin; GvHD, graft-versus-host disease; HSCT, hematopoietic stem cell
transplantation; MidAC, mitoxantrone, cytarabine.
Table A3. Comparison of Morphologic Marrow Status and MRD Level at End of Induction in Patients With B-Precursor ALL
B-Precursor ALL
BM at Day 29
MRD at End of Induction
MRD , 0.01% 0.01% # MRD , 0.1% 0.1% # MRD , 1% 1% # MRD , 5% MRD . 5% Indeterminate Total
M1 1,331 448 226 66 33 270 2,374
M2 5 1 6 3 16 3 34
M3 0 0 1 0 6 1 8
NR 161 47 29 10 6 58 311
Total 1,497 496 262 79 61 332 2,727
NOTE. Data indicate No. of patients within each group.
Abbreviations: ALL, acute lymphoblastic leukemia; BM, bone marrow; MRD, minimal residual disease; NR, not recorded.
Table A4. Comparison of Morphologic Marrow Status and MRD Level at End of Induction in Patients With T-ALL
T-ALL
BM at Day 29
MRD at the End of Induction
MRD , 0.01% 0.01% # MRD , 0.1% 0.1% # MRD , 1% 1% # MRD , 5% MRD . 5% Indeterminate Total
M1 103 52 54 15 21 74 319
M2 1 0 1 1 1 6 10
M3 0 0 0 0 3 4 7
NR 15 9 5 1 1 19 50
Total 119 61 60 17 26 103 386
NOTE. Data indicate No. of patients within each group.
Abbreviations: ALL, acute lymphoblastic leukemia; BM, bone marrow; MRD, minimal residual disease; NR, not recorded.
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Table A5. Characteristics of Patients With Induction Failure Defined by Morphology and MRD Level
Characteristic Total (n = 3,113) Indeterminate (n = 698) Remission (n = 2,295) Induction Failure (n = 120) P*
Patient
Sex
Male 1,767 (57%) 400 (57%) 1,296 (56%) 71 (59%) .6
Female 1,346 (43%) 298 (43%) 999 (44%) 49 (41%)
Age group, years
, 10 2,278 (73%) 496 (71%) 1,737 (76%) 45 (38%) , .001
10-15 608 (20%) 144 (21%) 420 (18%) 44 (37%)
$ 16 227 (7%) 58 (8%) 138 (6%) 31 (26%)
Median (range) 5 (1-24) 5 (1-24) 4 (1-24) 13 (1-24) , .001
Ethnicity
Black 74 (2%) 17 (2%) 56 (2%) 1 (1%) .4
White 2,525 (81%) 538 (77%) 1,882 (82%) 105 (88%) (.1†)
Asian 232 (7%) 66 (9%) 161 (7%) 5 (4%)
Other 151 (5%) 35 (5%) 111 (5%) 5 (4%)
Unknown 131 (4%) 42 (6%) 85 (4%) 4 (3%)
Down’s syndrome
No 3,026 (97%) 675 (97%) 2,236 (97%) 115 (96%) .3
Yes 87 (3%) 23 (3%) 59 (3%) 5 (4%)
Disease
WBC at diagnosis, 3109/L
, 20 1,904 (61%) 463 (66%) 1,385 (60%) 56 (47%) , .001
20- 524 (17%) 93 (13%) 414 (18%) 17 (14%)
50- 313 (10%) 63 (9%) 235 (10%) 15 (13%)
100- 199 (6%) 40 (6%) 146 (6%) 13 (11%)
$ 200 173 (6%) 39 (6%) 115 (5%) 19 (16%)
Median (range) 12 (0-881) 9 (0-783) 13 (1-881) 26 (1-800) , .001
NCI risk group
Standard 1,812 (58%) 399 (57%) 1,384 (60%) 29 (24%) , .001
High 1,301 (42%) 299 (43%) 911 (40%) 91 (76%)
Immunophenotype
B-precursor 2,727 (88%) 575 (82%) 2,071 (90%) 81 (68%) , .001
T-cell 386 (12%) 123 (18%) 224 (10%) 39 (33%)
Cytogenetic risk group‡
Good 1,586 (58%) 317 (55%) 1,251 (60%) 18 (22%) , .001§
Intermediate 860 (32%) 182 (32%) 635 (31%) 43 (53%)
High 121 (4%) 30 (5%) 80 (4%) 11 (14%)
Unknown 160 (6%) 46 (8%) 105 (5%) 9 (11%)
CNS disease at diagnosis
No 3,061 (98%) 684 (98%) 2,260 (98%) 117 (98%) .4
Yes 52 (2%) 14 (2%) 35 (2%) 3 (3%)
Treatment
Slow early response
No 2,751 (88%) 621 (89%) 2,075 (90%) 55 (46%) , .001
Yes 362 (12%) 77 (11%) 220 (10%) 65 (54%)
Bone marrow status day 29
M1 2,693 (87%) 344 (49%) 2,295 (100%) 54 (45%) N/A
M2 44 (1%) 0 (0%) 0 (0%) 44 (37%)
M3 15 (0%) 0 (0%) 0 (0%) 15 (13%)
Unknown 361 (12%) 354 (51%) 0 (0%) 7 (6%)
MRD level day 29
, 0.01% 1,616 (52%) 176 (25%) 1,434 (62%) 6 (5%) , .001
0.01%-1% 879 (28%) 90 (13%) 780 (34%) 9 (8%)
. 1% 183 (6%) 11 (2%) 81 (4%) 91 (76%)
Unknown 435 (14%) 421 (60%) 0 (0%) 14 (12%)
Regimen administered
A 1,537 (49%) 362 (52%) 1,162 (51%) 13 (11%) , .001
B 842 (27%) 214 (31%) 609 (27%) 19 (16%)
C 734 (24%) 122 (17%) 524 (23%) 88 (73%)
Abbreviations: MRD, minimal residual disease; N/A, not applicable; NCI, National Cancer Institute; WBC, white blood cell.
*P value for trend for ordered groups: age group, WBC, cytogenetic risk group, MRD level; otherwise, P value for heterogeneity. ‘Unknown’ category excluded.
†White v black, Asian, and other.
‡Risk groups defined for B-precursor acute lymphoblastic leukemia. Good risk cytogenetics = ETV6-RUNX1, high hyperdiploidy; high risk = near haploidy, low
hypodiploidy, KMT2A(MLL), iAMP21, t(17;19); intermediate = all others.
§B-precursor ALL only: good v intermediate v high.
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Table A6. Univariate Analysis of Factors Influencing EFS in Induction Failure Defined by Morphology and MRD
Characteristic Events/Patients 5-Year EFS (95% CI) P (log rank)
Patient
Sex
Male 37/71 43.8 (31.2 to 56.5) .5
Female 22/49 53.9 (39.6 to 68.1)
Age, years
, 10 17/45 59.1 (45.5 to 76.7) .003*
10-15 23/44 45.7 (32.7 to 63.9)
$ 16 19/31 35.9 (21.5 to 60.0)
Down’s syndrome
Yes 4/5 40.0 (0 to 82.9) .01
No 55/115 49.4 (39.7 to 59.1)
Disease
WCC at diagnosis
, 20 12/36 64.8 (48.5 to 81.0) .003*
20- 10/20 36.8 (9.0 to 64.7)
50- 8/17 50.3 (25.4 to 75.2)
100- 7/15 53.3 (28.1 to 78.6)
200- 22/32 30.6 (14.3 to 46.8)
NCI risk group
Standard 10/29 62.0 (42.9 to 81.1) .03
High 49/91 44.1 (33.4 to 54.7)
Immunophenotype
T cell 20/39 47.3 (31.1 to 63.5) .7
B precursor 38/76 47.8 (36.0 to 59.6)
Cytogenetic risk group (B-precursor ALL only)
Good 5/18 70.8 (49.3 to 92.4) .03†
Intermediate 24/43 40.9 (24.8 to 57.0)
High 5/11 53.0 (22.7 to 83.4)
Treatment
Early response
Rapid 25/55 51.3 (37.0 to 65.5) .4
Slow 34/65 45.4 (32.8 to 58.1)
Bone marrow status day 29
M1 27/54 47.0 (32.9 to 61.1) .2
M2 18/44 57.1 (41.8 to 72.4) (.4*)
M3 10/15 33.3 (9.5 to 57.2)
Regimen administered
A 4/13 63.9 (35.0 to 92.8) .4*
B 12/19 33.8 (11.3 to 56.4)
C 43/88 49.3 (38.5 to 60.2)
MRD level day 29
, 0.01% 0/6 100.0 .006*
0.01 to , 1% 2/9 76.2 (47.2 to 100.0)
1 to , 5% 1/4 75.0 (32.6 to 100.0)
$ 5% 47/87 43.2 (32.2 to 54.3)
Abbreviations: ALL, acute lymphoblastic leukemia; EFS, event-free survival; MRD, minimal residual disease; NCI, National Cancer Institute; WCC, white blood cell
count.
*Trend P values are a test across ordered groups.
†Good v intermediate/high.
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Table A7. Comparison of Morphological Marrow Status and MRD Level at the End of Induction in Patients with Early T-Precursor ALL
Early T-Precursor ALL
BM at Day 29
MRD at End of Induction
MRD , 0.01% 0.01% # MRD , 0.1% 0.1% # MRD , 1% 1% # MRD , 5% MRD . 5% Indeterminate Total
M1 3 1 5 3 3 12 27
M2 0 0 0 0 0 0 0
M3 0 0 0 0 1 0 1
NR 0 1 0 0 0 4 5
Total 3 2 5 3 4 16 33
NOTE. Data indicate No. of patients within each group.
Abbreviations: ALL, acute lymphoblastic leukemia; BM, bone marrow; MRD, minimal residual disease; NR, not recorded.
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